BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38042497)

  • 1. Dosimetric predictors of radiation pneumonitis in patients with prior immunotherapy exposure: A multi-institutional analysis.
    Bi J; Meng R; Yang D; Li Y; Cai J; Zhang L; Qian J; Xue X; Hu S; Yuan Z; Verma V; Bi N; Han G
    Radiother Oncol; 2024 Jan; 190():110040. PubMed ID: 38042497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors.
    Bi J; Qian J; Yang D; Sun L; Lin S; Li Y; Xue X; Nie T; Verma V; Han G
    Front Immunol; 2021; 12():828858. PubMed ID: 35095930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer.
    Lu X; Wang J; Zhang T; Zhou Z; Deng L; Wang X; Wang W; Liu W; Tang W; Wang Z; Wang J; Jiang W; Bi N; Wang L
    Front Immunol; 2022; 13():918787. PubMed ID: 35795657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of dosimetric factors with the development of symptomatic radiation pneumonitis in stereotactic body radiotherapy.
    Ryckman JM; Baine M; Carmicheal J; Osayande F; Sleightholm R; Samson K; Zheng D; Zhen W; Lin C; Zhang C
    Radiat Oncol; 2020 Feb; 15(1):33. PubMed ID: 32054487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
    Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
    Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel.
    Barriger RB; Fakiris AJ; Hanna N; Yu M; Mantravadi P; McGarry RC
    Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1381-6. PubMed ID: 20231061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic analysis of radiation pneumonitis: carbon-ion radiotherapy in patients with locally advanced lung cancer.
    Hayashi K; Yamamoto N; Karube M; Nakajima M; Matsufuji N; Tsuji H; Ogawa K; Kamada T
    Radiat Oncol; 2017 May; 12(1):91. PubMed ID: 28558766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of dosimetric parameters, clinical factors, and radiomics to predict symptomatic radiation pneumonitis in lung cancer patients undergoing combined immunotherapy and radiotherapy.
    Nie T; Chen Z; Cai J; Ai S; Xue X; Yuan M; Li C; Shi L; Liu Y; Verma V; Bi J; Han G; Yuan Z
    Radiother Oncol; 2024 Jan; 190():110047. PubMed ID: 38070685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of radiation pneumonitis following high-dose thoracic radiation therapy by 3 Gy/fraction for non-small cell lung cancer: analysis of clinical and dosimetric factors.
    Oh D; Ahn YC; Park HC; Lim DH; Han Y
    Jpn J Clin Oncol; 2009 Mar; 39(3):151-7. PubMed ID: 19193653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study.
    Jang JY; Kim SS; Song SY; Kim YJ; Kim SW; Choi EK
    Radiat Oncol; 2021 Dec; 16(1):231. PubMed ID: 34863244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excluding PTV from lung volume may better predict radiation pneumonitis for intensity modulated radiation therapy in lung cancer patients.
    Meng Y; Yang H; Wang W; Tang X; Jiang C; Shen Y; Luo W
    Radiat Oncol; 2019 Jan; 14(1):7. PubMed ID: 30642354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation.
    Ren C; Ji T; Liu T; Dang J; Li G
    Radiat Oncol; 2018 Apr; 13(1):69. PubMed ID: 29661254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis.
    Claude L; PĂ©rol D; Ginestet C; Falchero L; Arpin D; Vincent M; Martel I; Hominal S; Cordier JF; Carrie C
    Radiother Oncol; 2004 May; 71(2):175-81. PubMed ID: 15110451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitors.
    Shaverdian N; Beattie J; Thor M; Offin M; Shepherd AF; Gelblum DY; Wu AJ; Simone CB; Hellmann MD; Chaft JE; Rimner A; Gomez DR
    Ann Oncol; 2020 Dec; 31(12):1719-1724. PubMed ID: 33010460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of the predictors for radiation pneumonitis in patient with non-small cell lung cancer received radiotherapy after pneumonectomy.
    Yu JH; Wang CL; Liu Y; Wang JM; Lv CX; Liu J; Zhang Q; Fu XL; Cai XW
    Cancer Radiother; 2021 Jun; 25(4):323-329. PubMed ID: 33446419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary dose-volume predictors of radiation pneumonitis following stereotactic body radiation therapy.
    Harder EM; Park HS; Chen ZJ; Decker RH
    Pract Radiat Oncol; 2016; 6(6):e353-e359. PubMed ID: 27156424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Low dose volume histogram analysis of the lungs in prediction of acute radiation pneumonitis in patients with esophageal cancer treated with three-dimensional conformal radiotherapy].
    Shen WB; Zhu SC; Gao HM; Li YM; Liu ZK; Li J; Su JW; Wan J
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):45-9. PubMed ID: 23648300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of Effective Dose as a Better Predictor of Radiation Pneumonitis Risk Than Mean Lung Dose: Secondary Analysis of a Randomized Trial.
    Tucker SL; Xu T; Paganetti H; Deist T; Verma V; Choi N; Mohan R; Liao Z
    Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):403-410. PubMed ID: 30291994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-Volume Predictors of Radiation Pneumonitis After Thoracic Hypofractionated Radiation Therapy.
    Sasse A; Oh P; Saeed N; Yang DX; Hayman TJ; Knowlton CA; Peters GW; Campbell A; Laird J; Housri N; Park HS
    Pract Radiat Oncol; 2024; 14(2):e97-e104. PubMed ID: 37984711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exclusion of emphysematous lung from dose-volume estimates of risk improves prediction of radiation pneumonitis.
    Uchida Y; Tsugawa T; Tanaka-Mizuno S; Noma K; Aoki K; Shigemori W; Nakagawa H; Kinose D; Yamaguchi M; Osawa M; Ogawa E; Nakano Y
    Radiat Oncol; 2017 Oct; 12(1):160. PubMed ID: 28969651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.